317 related articles for article (PubMed ID: 31582045)
1. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
2. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
3. Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.
Delgado-López PD; Riñones-Mena E; Corrales-García EM
Clin Transl Oncol; 2018 Aug; 20(8):939-953. PubMed ID: 29218626
[TBL] [Abstract][Full Text] [Related]
4. Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis.
Siepmann DB; Siegel A; Lewis PJ
Clin Nucl Med; 2005 Mar; 30(3):199-200. PubMed ID: 15722830
[No Abstract] [Full Text] [Related]
5. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
[TBL] [Abstract][Full Text] [Related]
6. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
7. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.
Zikou A; Sioka C; Alexiou GA; Fotopoulos A; Voulgaris S; Argyropoulou MI
Contrast Media Mol Imaging; 2018; 2018():6828396. PubMed ID: 30627060
[TBL] [Abstract][Full Text] [Related]
8. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
[TBL] [Abstract][Full Text] [Related]
9. Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.
Ismail M; Hill V; Statsevych V; Huang R; Prasanna P; Correa R; Singh G; Bera K; Beig N; Thawani R; Madabhushi A; Aahluwalia M; Tiwari P
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2187-2193. PubMed ID: 30385468
[TBL] [Abstract][Full Text] [Related]
10. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.
Ellingson BM; Chung C; Pope WB; Boxerman JL; Kaufmann TJ
J Neurooncol; 2017 Sep; 134(3):495-504. PubMed ID: 28382534
[TBL] [Abstract][Full Text] [Related]
11. [Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Payer F
Wien Med Wochenschr; 2011 Jan; 161(1-2):13-9. PubMed ID: 21312094
[TBL] [Abstract][Full Text] [Related]
12. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy.
Wald LL; Nelson SJ; Day MR; Noworolski SE; Henry RG; Huhn SL; Chang S; Prados MD; Sneed PK; Larson DA; Wara WM; McDermott M; Dillon WP; Gutin PH; Vigneron DB
J Neurosurg; 1997 Oct; 87(4):525-34. PubMed ID: 9322843
[TBL] [Abstract][Full Text] [Related]
13. (18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.
Bolcaen J; Descamps B; Deblaere K; Boterberg T; De Vos Pharm F; Kalala JP; Van den Broecke C; Decrock E; Leybaert L; Vanhove C; Goethals I
Nucl Med Biol; 2015 Jan; 42(1):38-45. PubMed ID: 25218024
[TBL] [Abstract][Full Text] [Related]
14. Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas.
Yekula A; Muralidharan K; Rosh ZS; Youngkin AE; Kang KM; Balaj L; Carter BS
Adv Biosyst; 2020 Dec; 4(12):e2000029. PubMed ID: 32484293
[TBL] [Abstract][Full Text] [Related]
15. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.
Ellingson BM; Wen PY; Cloughesy TF
Neurotherapeutics; 2017 Apr; 14(2):307-320. PubMed ID: 28108885
[TBL] [Abstract][Full Text] [Related]
16. Incidence of intracranial radiation necrosis following postoperative radiation therapy for sinonasal malignancies.
Ahmad S; Le CH; Chiu AG; Chang EH
Laryngoscope; 2016 Nov; 126(11):2445-2450. PubMed ID: 27296477
[TBL] [Abstract][Full Text] [Related]
17. Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma.
Majós C; Cos M; Castañer S; Pons A; Gil M; Fernández-Coello A; Macià M; Bruna J; Aguilera C
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2224-2230. PubMed ID: 27609621
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
[TBL] [Abstract][Full Text] [Related]
19. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
Brahm CG; den Hollander MW; Enting RH; de Groot JC; Solouki AM; den Dunnen WFA; Heesters MAAM; Wagemakers M; Verheul HMW; de Vries EGE; Pruim J; Walenkamp AME
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2404-2412. PubMed ID: 30032322
[TBL] [Abstract][Full Text] [Related]
20. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Brandsma D; Stalpers L; Taal W; Sminia P; van den Bent MJ
Lancet Oncol; 2008 May; 9(5):453-61. PubMed ID: 18452856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
